VHIRhttp://www.vhir.org/salapremsa/noticies/noticies_paginacio.asp?page=1&mv1=5&mv2=3es-esIRHUV15"If you are a true scientist and confident about your data you will be the winner" (24/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=223&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0223\2014_0223_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Nobel Prize laureate in Medicine in 2005, Professor Barry J. Marshall, is the responsible of the paradigm shift in the treatment of stomach ulcers. For many years, the scientific community associated this disease with factors such as stress, and no one could conceive that bacteria could survive in the stomach. Prof. Marshall did it, but during 10 years he was much criticized. Eventually, he showed that the bacterium Helicobacter pylori is the cause of most peptic ulcers, and consequently, the disease can be cured with antibiotics.&nbsp; On October 19, Marshall gave the opening lecture of the World Health Summit 2014, where we met him to know more about his experience as a researcher. How did you feel when everybody said that you were wrong in that time? Were you frustrated, angry or just the opposite? My answer to that is that science is not a democracy. If you are a true scientist and you are confident about your own data, you don’t need to worry about everybody being against you. You know that eventually, you’ll be the winner. And the most simple, cost-effective solution to any problem is going to be the ultimate successful one. I knew that eventually everybody would want to use antibiotics. At that time, did you have the support of a PI or your boss? It took me two years of trying before I had any finding. And after that, I didn’t need any boss because I had my own money and my own salary from the Australian research funding agency. Peer review funding is good, but originally with a funny idea or strange theory you don’t have any peers, so you have to develop some collaborators or supporters. Then with the initial very small thing you do, that in my case was a post, you have a few supporters that will help you to talk to more senior people, who can mentor you, give you some advice and make suggestions. However, you don’t have to take the suggestions because they are often the guides. But that’s when you start, and that might connect you with the right networks. In my case, ultimately within two years, I had national and international supporters. In 1984 you drank a huge amount of helicobacters. What led you to do this? <span st</td></tr></table>comunica@vhir.org (VHIR)Fri, 24 Oct 2014 00:00:00 GMT"The recovery of Teresa Romero will foster the research in ebola" (23/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=222&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0222\2014_0222_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Doctor Diana Pou, member of the Infectious Diseases group at Vall d’Hebron Institute of Research (VHIR) and the Catalan program for international health (PROSICS), is a consultant of the scientific committee of Ebola in Spain at the Instituto de Salud Carlos III (ISCIII) of the Spanish government. Pou worked in Africa with Médecins Sans Frontières for several periods in 9 years, and has experienced in first person 3 ebola outbreaks. For the specialist in tropical medicine, the recovery of the Spanish nurse assistant, Teresa Romero, “opens the door to the research in ebola”. According to the Spanish news agency EFE, she assured that pharmaceutical companies are who decide when will arrive the first drug for ebola. Nonetheless, since this case, “the expectations in the knowledge of the virus, the disease, the possible treatments and the vaccines have increased” Pou reported. The physician was interviewed in TV3 and 8TV, where she explained her experience as a consultant of the Spanish government. She also explained that there is still a long shot of new cases in Spain, and insisted on the need to manage what she considers an ‘epidemic of fear’ among the society. </td></tr></table>comunica@vhir.org (VHIR)Thu, 23 Oct 2014 00:00:00 GMTStudy in young male prisoners suggest that aggression can be reduced by treating ADHD (22/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=221&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0221\2014_0221_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> At an international meeting held by the Aggressotype Consortium in Mainz, Germany, researchers from King’s College and Imperial College London presented preliminary results from an on-going treatment study of ADHD in young male prisoners. A team of researchers from the group of Psychiatry, mental health and addictions, at the Vall d’Hebron Research Institute (VHIR), led by Dr. Josep Antoni Ramos-Quiroga, is participating in this study through the Aggressotype Consortium. The preliminary results show that 20% of the prisoners met clinical criteria for ADHD. After medical treatment with a long acting stimulant medication there was a large reduction in ADHD symptoms. Improvements with ability to focus attention, restless over activity and impulsive responding were accompanied by greater self-control of behavior and ability to engage positively in educational and rehabilitation programs. Participants reported being less frustrated, irritable and angry, and there was a reduction in aggressive incidents. Aggressotype is a large international consortium funded by the European Union consisting of 18 academic and 6 commercial partners. Aggressotype researchers aim to unravel the biological causes and mechanisms underlying aggression in ADHD and conduct disorder and also investigate how aggression can best be prevented and treated. In their annual meeting this October, the 60 researchers discussed the progress made during a successful first year of their 5-year project, with issues presented covering a wide range of disciplines. Aggressotype represents a unique mix of people with skills and expertise in neuropsychiatry, neuropsychology, preclinical animal and in vitro models, neuroimaging and neurochemistry, genetics and genomics, epigenetics, bioinformatics and biostatistics, clinical pharmacology, regulatory affairs, ethics, valorisation and project management. </td></tr></table>comunica@vhir.org (VHIR)Wed, 22 Oct 2014 00:00:00 GMTThe project 'Global Tele Rehabilitation System' improves the mobility of patients after a stroke (21/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=220&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Global Tele Rehabilitation System project (GTRS), promoted by the Vall d’Hebron Research Institute (VHIR) with the support of Fundación Vodafone España, has developed a solution for patients after suffering a stroke that allows them to do the rehabilitation at home under the control of a medical team. After a year and a half of trials, the initiative has concluded with excellent results. The solution, created by the I2Cat Foundation, consists on a series of personalized exercises presented as a game that patients have to follow in order to improve mobility on the parts affected after the stroke. The system records the exercises to facilitate the evolution of treatment and includes programmed videoconferences so that doctors and patients can chat about the rehabilitation process. The system, from the patient side, consists of a computer equipped with a touch screen, a Microsoft Kinect sensor and a mobile broadband internet connection provided by the 4G Vodafone network. The application has been used by 30 patients from different ages that have a disability because of a stroke, and they have followed a treatment during four weeks in each one of the 4 available devices. Besides the devices, the Occupational Therapy Unit at the Vall d’Hebron University Hospital (HUVH), as well as the rehabilitation team lead by Dr. Inmaculada Bori, have had a key role in the clinical follow-up of the cases. Patients are really satisfied with the results of the day-to-day treatment. Now the pilot study is over, all the equipment will be incorporated to the normal practice to keep being of use to new patients. They are also studying the possibility of establishing these equipment in different rehabilitation centers. The study, that has just concluded and its results will be presented in the next congress of the Sociedad Española de Neurología, has shown that the use at home of the system GTRS during 4 weeks induces a general improvement in the mobility of upper extremities of patients. All participants, patients and professionals, have coincided in valuing positively the tool and most of them regretted not being able to use it longer. Dr. Marc Ribó, neurologist at the Ictus Unit of the HUVH, ensures that the system is “a step forward, which makes rehabilitation easier and saves time and money for the patient and for the public health system”. The challenge now is that the system also improves the mobility on inferior extremities, as well as using it for other disabilities. </td></tr></table>comunica@vhir.org (VHIR)Tue, 21 Oct 2014 00:00:00 GMTThe race 'Nick Horta' raises 8,000 euros for hepatic cancer (21/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=180&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0180\2014_0180_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The V Cursa Nick Sport d'Horta, the charity race that took place the September 21th and this year was dedicated to hepatic cancer at the Vall d’Hebron Institut de Recerca (VHIR), was a success with 1,000 runners registered and 8,000 euros raised for research on this disease, at VHIR. María José Moscoso, the promoter of the race, has given the cheque to VHIR's Director, Joan X. Comella, together with Gemma Flores, director of the Nick Sports center. Moscoso it’s been 9 months since she got a liver transplant at Vall d’Hebron, after she was diagnosed with hepatic cancer. The day of the race she gave a symbolic cheque to Dr. Ramon Charcho, head of the digestive transplants group at VHIR. “I feel that I must help all the people who have been with me and the Catalan public system of health”, said María José, that admitted that “I consider my duty to compensate somehow all the things that the doctors have done to keep me alive and healthy”. This is the reason why the last two years the charity race has dedicated all funds to the research at VHIR; the goal is to collect more funds than last year that raised nearly 5,000 euro. The main novelty for this year event was a free special race for young people and children with Down syndrome or any other disability that joined the race in the last 1.5km. </td></tr></table>comunica@vhir.org (VHIR)Tue, 21 Oct 2014 00:00:00 GMTVHIR researchers unveil the role of a key protein in the reparation of the damage caused by the solar radiation (16/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=218&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0218\2014_0218_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers of the Melanoma group at the Vall d’Hebron Institute of Research (VHIR), integrated by professionals from the services of Dermatology, Oncology and Pathology, and led by Dr. Juan Ángel Recio, discovered that a protein, called LKB1, is essential to trigger the process of reparation of the DNA damage caused by solar radiation.&nbsp; The landmark, published in Plos Genetics, paves the way for the use of the protein as a prognostic factor in patients with ultraviolet induced skin cancer. Ultraviolet radiation has been associated to the acquisition of different types of skin cancer and premature skin aging. It causes modifications in the genetic material of cells (DNA) that if not repaired properly will lead to a mutated DNA which might trigger the development of cancer. In fact, several studies conclude that people who overexposed to the sun during their childhood are more likely to develop melanoma at the age of 50 and above. For that reason, understanding the molecular basis of the ultraviolet-induced DNA damage response is important to elucidate the mechanisms of skin tumorigenesis. The aim of the study was to determine the causes that lead to the development of skin cancer due to ultraviolet radiation. Particularly, they wanted to unveil how LKB1, which is a mutant protein in humans, participates in these processes. Firstly, the authors used a UV-induced skin cancer mouse model, where one of the two Lkb1 gene alleles was deleted, and consequently the amounts of LKB1 protein was of half the normal levels. A single dose of ultraviolet radiation in Lkb1 neonate mice was enough to induce the quick development of squamous cell carcinomas, and this was associated to a deficient response in DNA damage repair. This single dose of radiation is the equivalent to three hours of exposure to the sun without any protection in summer. The results were surprising, Dr. Recio reported, because the animals developed skin cancer five months before the expected date: “mice with the protein inactivated in one allel developed, in just one month, a type of cancer that use to suffer farmers, fishermen or people who has been exposed to the sun for a long period in their life”, explained Dr. Recio. Moreover, cells harboring the damaged DNA were resistant to cell death (apoptosis). Thus, as Dr. Recio said, lack of LKB1 promotes a double effect: “cells not only fail to repair the damage in their DNA, but they do not die, leading to the accumulation of mutated cells and the development of tumors”. The research team has obtained similar results (to be published soon) in two additional mouse models of melanoma, a much more lethal type of UV-induced skin cancer. In the near future, Dr. Recio’s team will be evaluating LKB1 as a prognostic risk factor for ultraviolet–induced skin cancer. They also are investigating the different factors that may alter LKB1 expression, with a particular emphasis in families with skin cancer predisposition or skin cancer history. </td></tr></table>comunica@vhir.org (VHIR)Thu, 16 Oct 2014 00:00:00 GMTTwo VHIR platforms become facilities of the Spanish Map of Singular Scientific and Technical Infrastructures (16/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=219&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0219\2014_0219_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The council of Political Science, Technology and Innovation approved the new so-called Spanish Map of Singular and Technical Infrastructures (ICTS) that, for the first time, includes two platforms of the Vall d’Hebron Institute of Research (VHIR). These platforms are the Area of Functional Validation and Preclinical Research (FVPR), managed by the CIBBIM-Nanomedicine, and the Molecular Imaging Platform, located in the Animal Facilities of the Institute. Both infrastructures are integrated in the Spanish network of biomedical research in bioengineering, biomaterials and nanomedicine (CIBER-BBN). The FVPR aims to provide the industry and other research groups with an optimum technical platform for testing new biomedical applications based on the nanotechnology from compounds for the treatment of specific diseases to new applications in diagnosis and imaging. One of the services of the FVPR is the Molecular Imaging Platform, established through the common efforts of CIBER-BBN, CIBBIM-Nanomedicina and VHIR, as a service to research groups and pharmaceutical companies. Its mission consists in provide the capacity to develop noninvasive optical image in vivo at cellular, molecular and functional level, including fluorescence and bioluminescence. Both services are part, together with 27 Spanish infrastructures, of the NANBIOSIS platform, which is devoted to produce and characterize nanomaterials, biomaterials and biomedical systems at the CIBER-BBN. This platform is oriented towards medical applications and aims to give an easy full service to researchers. It includes the design, production of biomaterials and nanomaterials, the characterization of these materials and tissues, and the development of medical devices and systems from a physical, chemical, functional, toxicological and biological point of view, including the preclinical validation (which is the part carried out at VHIR). The new map approved by the government has 29 ICTS that include a total of 59 infrastructures. All of them passed a rigorous assessment process and demonstrated their economic sustainability. </td></tr></table>comunica@vhir.org (VHIR)Thu, 16 Oct 2014 00:00:00 GMTThe town of Sant Mateu collaborates in the research against colorectal cancer (15/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=216&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0216\2014_0216_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Mamma Mia musical, played in Sant Mateu by an amateur company from Vinaròs, beat the expectations of the organizers, who counted nearly 2,000 visitors. It is in fact a high number of people, taking into account that this town located in the Maestrat has more or less the same number of inhabitants. The tickets were free, but instead, the party committee asked for donations to support the research in colorectal cancer carried out at the Vall d’Hebron Institute of Research (VHIR). They raised more than 4.300 euros that will fund the research of the Molecular Oncology group at CIBBIM, led by Dr. Diego Arango. Dr. Arango received in his lab the members of the party committee, in order to thank them for the initiative and to tell them the research that he leads at VHIR. His group works in two main research lines: one focused in the biology of the disease with the objective to personalize treatments, and the other one aims to identify biomarkers to improve the survival of colorectal cancer patients. </td></tr></table>comunica@vhir.org (VHIR)Wed, 15 Oct 2014 00:00:00 GMTAnnals of Neurology recognizes a study by Dr Vila as 'paper of the year' (15/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=217&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0217\2014_0217_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The editorial board of the Annals of Neurology, the journal of the American Neurological Association, and its Editor-in-chief Prof. Clifford Saper, awarded the “Paper of the Year” prize to a study led by Dr. Miquel Vila, ICREA researcher, leader of the Neurodegenerative Diseases Group of the VHIR, and member of CIBERNED.&nbsp; The study shows that pathological forms of the alfa-synuclein protein present in the brain of deceased Parkinson Disease (PD) patients were capable of initiating a PD-like pathological process in mice and primates. For the authors, these findings provide new information on how the disease is initiated and amplified. The study, published in February 2014, in the Annals of Neurology, involved the participation of other CIBERNED groups from the University of Valencia and the University of Navarra, as well as researchers from the University of Bordeaux, France.&nbsp; The award will be presented during the next American Neurological Association meeting in Baltimore, Maryland, October 12-14.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Wed, 15 Oct 2014 00:00:00 GMTExperts in the application of genomics in biomedicine meet at VHIR (14/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=214&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0214\2014_0214_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The meeting “The impact of genomics in translational medicine: present view”, held last Monday October 13 in the Vall d’Hebron Institut de Recerca (VHIR), brought together a group of experts in the application of genomic techniques in biomedicine with two main objectives: bring these techniques closes to our community, and analyzing how they apply and the problems said application bring. The first speaker, Dr. Joaquín Dopazo, heaf of the group of Computational Genomics at the Centro de Investigación Príncipe Felipe (CIPF), explained to the researchers of the institute how they can use different sequencing techniques in order to identify pathological variables in the genome of the patients. After his speech, Dr. Ivo Gut, director of the Centro Nacional de Análisis Genómico, approached some international projects in which genomic information is key for the better understanding of rare diseases and cancer. The third speaker, Dr. Manel Esteller, director of the Epigenetic and Biology of Cancer program at IDIBELL, recalled that the genetic effects are just one small part of the molecular causes of the disease, and that massive epigenetic analysis can have an important diagnostic value. Finally, Dr. Xavier de la Cruz, head of the Translational Bioinformatics research group at VHIR, presented the techniques for the identification of pathological mutations to the sequencing problems, its limits and possibilities of improvement. <p style=" text-align: left; text-indent: 0px; padding: 0px </td></tr></table>comunica@vhir.org (VHIR)Tue, 14 Oct 2014 00:00:00 GMTA day of hope for patients with multiple myeloma (14/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=215&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0215\2014_0215_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> More than a hundred patients with myeloma (bone marrow cancer) and their families took part on the 1st Meeting for patients in Spain, last Saturday in the Vall d’Hebron University Hospital, with the aim to open dialogue with the best researchers in the disease in Spain that are, also, among the world elite. The meeting was organized by Patient Power, the Vall d’Hebron Institute of Research (VHIR) and the Catalan Institute of Oncology. Doctors Mercè Gironella, responsible of Myeloma at the Vall d’Hebron Hospital and researcher at VHIR; Albert Oriol, from the Catalan Institute of Oncology; María Victoria Mateos, from the University Hospital of Salamanca; and Francesc Bosch, head of Hematology at the Vall d’Hebron Hospital and VHIR, sent an optimistic message. Dr Bosch explained that “at the rate we are going, we will be able to cure some cancers in 10 or 15 years”. Actually, treatments nowadays allow most of the patients a good quality of life during quite some years. Elisa, patient of myeloma for many years, explained that “I go ahead, have a normal life, even now that I have relapsed, and even at a time I lost my ability to walk”. Mercè, another patient, explained that it’s been 11 years since she was diagnosed and that she goes ahead “thanks to the doctors”. In the last years powerful medicine has been released that allow treating the patient once he or she relapses and, moreover, are less toxic than years ago. What is clear is that patients are now active part of the fight against the disease: “Before there was a tennis match between the doctor and the diseased; now it is a doubles match against the myeloma”<span style=" font-size: 8pt; </td></tr></table>comunica@vhir.org (VHIR)Tue, 14 Oct 2014 00:00:00 GMTVHIR selects Macrogen as the genomics service partner (13/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=212&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0212\2014_0212_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Vall d’Hebron Institute of Research and the world-leading Genomics services company Macrogen announced that they had signed a comprehensive Genomics service partnership agreement including Macrogen X-Genome (the Xpressway to Genome) services. According to this agreement, Macrogen will provide various Genomics services including both the capillary sequencing service and the state-of-art next-generation sequencing (NGS) service to VHIR researchers. This agreement reinforces VHIR’ scientific and technical support services in an effort to strengthen its researcher’s capacity to discover and implement novel diagnosis and treatment measures. In this sense, VHIR’s researchers will benefit from the Macrogen-VHIR special program based on Macrogen’s comprehensive Genomics service portfolio. VHIR’s staff, composed of 1.200 researchers (mostly clinicians), is aimed to achieve a direct translation from research to applications, with the final goal of offering Vall d’Hebron Hospital patients the benefit of the most advanced knowledge. By means of this agreement, Macrogen will partner VHIR to achieve its objective. In fact, Macrogen is the only European provider of the Illumina HiSeq X Ten sequencing system based large-scale Human whole-genome sequencing service, also known as Macrogen’s ‘X-genome (the Xpressway to Genome)’ service. Optimized for large-scale human genome analysis projects, the HiSeq X Ten sequencing system is capable of analyzing the genomes of 16 people within 3 days for a cost of less than 1,000 dollars, giving rise to expectations that it will pave the way to a new era of human genome sequencing. In January of this year, Macrogen became the first commercial service provider to sign a preferred supply agreement for the HiSeq X Ten system with Illumina. </td></tr></table>comunica@vhir.org (VHIR)Mon, 13 Oct 2014 00:00:00 GMTDr. Sanchez de Toledo, recognized with the highest distinction of Rotary International (13/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=213&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0213\2014_0213_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Rotary International has awarded the Paul Harris distinction to Dr. José Sánchez de Toledo, head of the Translational Researh in Child Cancer at the Vall d’Hebron Institute of Research (VHIR), as recognition to his scientific and human career dedicated to the cure of children with cancer, and beating the disease. The award is the highest recognition that Rotary International gives for business excellence, community service and professional career. The prize was presented last Thursday October 9 in Barcelona, in the context of the celebration of a charity dinner, to raise funds for the research group in child cancer at VHIR. Dr. Sánchez de Toledo gave a conference in the celebration titled “Research for children with cancer. A better future”. The organization brought together eminent people from the health field, public and private institutions, companies, rotary authorities and civil society in general. Dr. Sánchez de Toledo is Doctor in medicine and Surgery for the Universitat Autònoma de Barcelona (UAB). Nowadays he is chief of Pediatric Oncology and Hematology at the Vall d’Hebron University Hospital, head of the research group on child cancer at VHIR, and associated professor of pediatrics at UAB. The Service he leads was pioneer in Spain, in 1984, on performing bone marrow transplants on children. Since then, the transplant unit has realized more than 1,100 cell transplants, more than twice any other Spanish hospital. Among other recognitions, in 2012 he received the price to Professional Excellence that gives the Col·legi de Metges de Barcelona and was chosen Catalan of the Year 2012. </td></tr></table>comunica@vhir.org (VHIR)Mon, 13 Oct 2014 00:00:00 GMTVHIR inaugurates the Master's Degree in Translational Biomedical Research (10/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=211&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0211\2014_0211_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> This Friday, October 10, the Vall d’Hebron Institute of Research (VHIR) has celebrated the opening day of the first edition of the Official Master’s Degree in Translational Biomedical Research. In the ceremony, a representative of Banco Santander, Pfizer, Promax, Fenin and the VHIR have given the 6 sponsored grants that will cover the full cost of registration to the students with the best qualifications. VHIR’s Director, Dr. Joan Comella, has transmitted to the 37 students enrolled in the master the passion, enthusiasm and illusion put by the researchers in the program; researchers that will train them in their specialties, as teachers of the master. The co-coordinator of the master, Dr. Anna Meseguer, has explained the details of the program that she has designed together with Dr. Francina Munell, with the aim of training researchers of excellence that will be able to contribute to the success of translational biomedical research in the future. The master is directed to a scientific career, gives access to the doctorate program, and offers the students the possibility of choosing an area in the biomedicine field in which to study and do their internships. At the ceremony were also present the Vice-Rector of Strategic Projects and Planification at UAB, Dr. Lluís Tort; the Assistencial Director at the Vall d’Hebron University Hospital, Dr. Jaume Roigé, and the Teaching Director at the Hospital, Dr. M. Josep Cerqueira. </td></tr></table>comunica@vhir.org (VHIR)Fri, 10 Oct 2014 00:00:00 GMTThe music parade La Murga de la Llagosta gets wet for ALS (09/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=206&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0206\2014_0206_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> For the first time in 30 years, the music parade “La Murga de la Llagosta” dedicated their celebration to the research in Amyotrophic Lateral Sclerosis (ALS), led at Vall d’Hebron Institute of Research (VHIR) by Dr. Josep Gámez. Antonio Melgar suffers this devastating disease and José Antonio Monterrubio’s mother died because of ALS. Both are members of “La Murga” and, coinciding with the successful Ice Bucket Challenge campaign, they decided to raise funds for research. Besides the music parade, they organized a big paella for all the participants, a contest of potato omelettes, a party for children and a concert of “habaneras”. With all these activities, they raised more than 1,100 euros that will fund the research carried out by the group of Peripheral Nervous System, led by Dr. Gámez. His group is currently working on three different research lines dedicated to the study of molecular mechanisms and genetic mutations of the disease. The group is also part of ALSUntangled, an international network of clinical experts with the aim of offering alternative or off-label ALS treatments. Besides the research team, the Vall d’Hebron University Hospital has an interdisciplinary unit devoted to the care of ALS patients, which serve nearly 100 out of the 400 affected that are in Catalunya. The cause of ALS is unknown and there is no cure or treatment available. It is a debilitating disease characterized by the loss of motor neurons which cause rapidly progressive weakness, muscle atrophy and the death of the patients by breathing failure. </td></tr></table>comunica@vhir.org (VHIR)Thu, 9 Oct 2014 00:00:00 GMTVall d'Hebron professionals have successfully tested a pioneer surgery that reduces the effects of the spina bifida in the fetus (08/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=204&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0204\2014_0204_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Since 2011, professionals from the Vall d’Hebron University Hospital have operated fetus diagnosed with myelomeningocele or spina bifida, which is a congenital disorder that affects the central nervous system and, in life, results in paralysis of the lower extremities with difficulty or inability to walk, as well as sphincter incontinence. Until now, the procedures were very complex: surgeons opened the uterus of the pregnant women between months 4 and 5, operated the back of the fetus in order to correct the defect, and then closed again the uterus. However, since 2013, the same professionals have successfully tested a surgery that reduces the effects of the spina bifida in the fetus, using a pioneer technique called fetoscopy. This procedure is minimally invasive because it only goes through the fetus’ back with a tiny endoscope. Once the defect is corrected, researchers seal the injury with a technique conceived and developed by Dr. César Galo García Fontecha, head of the Bioengineering, Orthopedics and Surgery in Pediatrics group at Vall d’Hebron Institute of Research (VHIR). </td></tr></table>comunica@vhir.org (VHIR)Wed, 8 Oct 2014 00:00:00 GMTThere is a strong association between renal failure and triglyceride levels in people with diabetes (06/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=203&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0203\2014_0203_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> An international study, performed by 24 hospitals and clinics from 13 different countries, among them the Vall d´Hebron Institut of Research (VHIR), with&nbsp; Drs. Rafael Simó and Cristina Hernández, shows that the levels of lipids in diabetic patients are clearly associated with the risk of developing renal failure. The study was published in the journal Circulation.&nbsp; The goal of the research was to determine whether triglyceride and cholesterol levels in the plasma are associated with diabetic kidney disease (nephropathy) and vision loss (retinopathy). The study shows that triglyceride and HDL-C levels are strongly, and independently, associated with the risk of developing microvascular disease, and in particular, kidney failure. This means that, even if the levels of “bad” cholesterol (LDL-C) in these patients are controlled by drugs, the probability that they will develop kidney failure is increased if they have high levels of triglycerides, whereas HDL-C diminish it. Triglycerides are a type of fat with a different function than cholesterol (they are a source of energy) and, when in high levels, can cause artherosclerosis and heart disease.&nbsp; As Dr. Simo points out, “controlling the levels of triglycerides not only decreases the cardiovascular risk but also curbs kidney disease, which is the main cause of end-stage renal disease and transplantation, with the economic cost it implies for the health system”. The risk of retinopathy is also associated with triglyceride levels, but the association is weaker and may depend on other factors such as hypertension and glycosilated hemoglobolin levels.&nbsp; For the authors, the strength of this study relies on its global scope: the multiple sites and the size of the sample (2635 cases and 3683 controls) supports wide applicability of the results across different regions and ethnical groups. Diabetes mellitus is the main cause of kidney failure and blindness in adults. Its worldwide prevalence is on the rise, and the complications associated to the disease are also expected to increase. Even though glucose and tension control can limit the development of diabetic microvascular disease, the residual risk for these complications remains high. Therefore, it is necessary to identify other targets and treatments to make progress in slowing the development of diabetic kidney disease and retinopathy.&nbsp; <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #555555; background-color: transpa</td></tr></table>comunica@vhir.org (VHIR)Mon, 6 Oct 2014 00:00:00 GMTVall d'Hebron launches the second fundraising campaign in the hospital grounds (03/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=202&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0202\2014_0202_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR) launched this week a fundraising campaign in the hospital facilities. During the following weeks, a team of fundraisers will inform the users and their companions about the opportunity to actively collaborate in the research carried out by their doctors. The Fundraising Unit of the VHIR launched this second campaign in order to attract new donors who will help to fund the training of pre-doctoral researchers. In the first campaign, more than 300 people became ‘friends of VHIR’. Thanks to them, two researchers will work and do their dissertation at the Institute in the next 3 years. The campaign started in the General Area and will also take place in the Maternal &amp; Child and Trauma &amp; Surgery areas, until November 28th. </td></tr></table>comunica@vhir.org (VHIR)Fri, 3 Oct 2014 00:00:00 GMT'Friends of VHIR' fund the pre-doc training of two researchers (02/10/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=201&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0201\2014_0201_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The 2013 call of the VHIR’s Programme for PhD students granted two additional researchers, Casandra Riera and Luz Jubierre, thanks to the donations of ‘friends of VHIR’. Casandra is graduated in Biotechnology at the Universitat Autònoma de Barcelona and holds the Master Degree in Molecular Biology of the Universitat de Barcelona. On 2012, she joined the Translational Bioinformatics group, led by Dr. Xavier de la Cruz, in order to carry out a project for the development of bioinformatic tools for the prediction of pathological mutations. Her dissertation will focus on this project for the next 3 years.  Luz is graduated in Biomedical Sciences at the Universitat the Barcelona and holds the Neurosciences Master Degree of the same university. Since 2012, she has done a stage with the Translational Research in Child Cancer group, coordinated by Dr. Josep Sánchez de Toledo, combining her studies of the double degree in Mathematics and Physics of the Universitat de Barcelona. Her dissertation, led by Dr. Miguel Segura, will be focused on epigenetic therapies against two types of child cancer: neuroblastoma and ependimoma. Both researchers started their grant funded by ‘friends of VHIR’ on October 1st, together with the four researchers who were also granted by the Institute in this 2013 edition. </td></tr></table>comunica@vhir.org (VHIR)Thu, 2 Oct 2014 00:00:00 GMTPeople with irritable bowel syndrome present increased activation of immune defenses in their small intestine (01/10/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=199&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0199\2014_0199_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> A team of VHIR researchers, led by Dr. Javier Santos and Dr. Maria Vicario, has discovered that people with diarrhea-predominant irritable bowel syndrome (IBS-D) present increased immune activity in their small intestine as compared to healthy persons. The results of the study have been recently published in the journal Gut and highlighted in the November issue of Nature Reviews, Gastroenterology and Hepatology. "Surprisingly, we have detected that patients with the disease have a higher number of antibody-producing cells in their jejunum than healthy subjects" explains Dr. Vicario. The majority of these antibodies are IgG immunoglobulins (Ig), which are more efficient than other types of Ig and are produced upon stimulation of B cells by specific antigens. By performing gene expression analysis, the research team revealed previously undescribed alterations at the molecular and cellular level that are associated to the clinical manifestations of the disease. "We found that the more activated the defenses in the intestine of these patients, the more severe are the symptoms", points out Dr. Vicario. The main symptoms of IBS are lower abdominal pain and modifications in stool frequency and consistency. To date, diagnosis of SII is established solely on the basis of clinical criteria and exclusion of other diseases.&nbsp; No reliable biomarkers exist, reason for which Dr. Santos underlines that "the results obtained in this study pave the way to the design of a test, based on the detection of immune activity in the intestine, to facilitate IBS diagnosis". The increased immune activation is detected in the small intestine but not in the blood of these patients, which indicates that it is a local event and explains why routine clinical analysis in these patients are often absolutely normal. IBS is a chronic and debilitating disease that affects approximately 15% of the population in developed countries. The chronicity of the disease, together with the lack of efficient therapies, significantly decreases the patient’s quality of life and represents a considerable health-care cost for society. </td></tr></table>comunica@vhir.org (VHIR)Wed, 1 Oct 2014 00:00:00 GMTVHIR Annual Report 2013 (30/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=198&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Welcome to the 2013 VHIR’s Annual Report: 20 Years committed to your health. Here you will find an interview with all the members of our Research Executive Committee and the manager director of HUVH, reviewing a year in which our institute is celebrating its 20th anniversary. This year you can watch videos of our research areas, explaining the activity of the different groups, and also images of the best of the innovation contest and a summary of the launching of the Master Degree in Translational Biomedical Research. Once again our scientific production –over the 4,000 total impact factor- and the findings of our researchers make of us one of the best and we want to share with you our most outstanding results. Links: - Multimedia Annual Report 2013 - Printable Annual Report 2013 <p style=" text-align: left; text-indent: 0px; padding: 0px 0px 0px 0px; margi</td></tr></table>comunica@vhir.org (VHIR)Tue, 30 Sep 2014 00:00:00 GMTPassengers aboard the Barcelona-France AVE learn how to use a defribillator (29/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=197&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0197\2014_0197_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Shock, Organ Dysfunction &amp; Resuscitation (SODIR) group of the Vall d’Hebron Institut de Recerca (VHIR) and the Intensive Care Unit of the Vall&nbsp; d'Hebron University Hospital joined the initiative “Un train d’avance pour la vie”. During 4 days more than 250 volunteers, trained by intensivist MDs, medical residents, nurse personnel and medicine students, taught Basic Life Support techniques and external semiautomatic defribillation to passengers travelling in the high-speed trains connecting Barcleona to Paris, Marseille, Lyon and Toulouse. The Catalan Society of Critical and Intensive Medicine appointed the SODIR researcher Dr. Juan Carlos Ruiz, as coordinator of the Basic Life Support and Resuscitation, together with Dr. A. Lesmes, project manager of the Plan Nacional de Reanimación Cardiopulmonar of the Spanish Society of Intensive Medicine and Coronary Units (SEMICYUC),&nbsp; to train the healthcare professionals that volunteered for the activity. With this action, intensive care specialists aimed to sensitize and familiarize the population with cardiopulmonary resuscitation procedures and the use of semiautomatic defribillators, so they can act in case of cardiac arrest. The initiative is led by LIFE Priority, a foundation belonging to the European Society of Intensive Care Medicine, that is currently celebrating its 27th Annual Congress in Barcelona. The World Heart Day is celebrated this Monday, and its goal is to promote preventive measures and raise awareness on the fight against cardiovascular diseases that, according to the World Heart Federation, are the first cause of mortality worldwide, causing 17.3 million deaths per year.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Mon, 29 Sep 2014 00:00:00 GMTThree VHIR professionals receive the Josep Trueta health merit medal 2014 (26/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=196&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0196\2014_0196_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Ferran Morell, head of the Pneumology group; Dr. Lluís Cabero, co-responsible of the Maternal Fetal Medicine group; and Dr. Mercè Canela, from the General Surgery group, have been awarded the health merit medal 2014, that give the Catalan Government. The awards ceremony has been presided by the catalan health regional minister, Boi Ruiz, with the vice-president of the Catalan Parliament, Núria de Gispert, in charge of giving the awards and closing the ceremony. The aim of the awards, which in this edition have been given to 9 people and 3 organizations, is to recognize their contribution to the advance and improvement of health. These awards were created in 1997, coinciding with the celebration of the centenary of the birth of the recognized Catalan doctor and scientist. Dr. Lluís Cabero Roura is co-responsible of the Maternal Fetal Medicine group, at the Vall d’Hebron Institut de Recerca (VHIR), and gynecologist at the Vall d’Hebron University Hospital. Degree in Medicine and Surgery from the UB, Doctor in Medicine and Surgery, and in Sciences and Biology. He was president of the Spanish Society of Gynecology and Obstetrics (1995-2003), president of the National Commission of Obstetrics and Gynecology of the Ministry of Education and Health (2000-2005), and president of the Commission Hospital Amic dels Nens UNICEF (1997-2006). He has also been vice-president of the MS Foundation and vice-president of the International Federation of Gynecology and Obstetrics (FIGO). Since 2009, he is Chair of the Capacity Building in Education and Training Committee de FIGO. He has also been appointed honorary member of several international societies. Nowadays, and since 1990, he is head of the service and Professor of Obstetrics and Gynecology at the Universitat Autònoma de Barcelona (UAB). Since 2000, he is director of the Obstetrics and Gynaecology Service at Quirón Clinic in Barcelona, and also presides the Bioethics Commission of the Spanish Society in the same clinic. Dr. Mercè Canela, from the General Surgery group at VHIR, is head of the Thoracic Surgery Service at the Vall d’Hebron University Hospital, and the reference in Catalunya for lung transplantation. Doctor of Medicine for the Universitat Autònoma de Barcelona. She is specialist in thoracic surgery. After working in different hospitals in Catalunya, on 1985 she joined the Germans Trias Hospital, where she became Clinical Chief of the Thoracic Surgery unit in 1995. She later joined the Vall d’Hebron University Hospital, where she achieved the maximum responsibility in the service, since 2009. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-styl</td></tr></table>comunica@vhir.org (VHIR)Fri, 26 Sep 2014 00:00:00 GMTThe world ultra trail champion sponsors the 6th race 'Los calderones' (23/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=195&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0195\2014_0195_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> On October 5th will take place the 6th edition of the race ‘Los calderones’, sponsored this time by the world ultra trail champion, Luis Alberto Hernando. All the funds collected will be delivered to the research in child cancer led at Vall d’Hebron Institute of Research (VHIR) by Dr. Josep Sánchez de Toledo. The dog training association ADCAN organizes once again this race with several options: a mountain race run, a crosscan, a race for children and a walk through the mountain. All these disciplines will take place in Otero de las Dueñas, a town located in the northeast of León. The organizers and the sponsor of the race visited today the children with cancer admitted to Vall d’Hebron University Hospital. They gave T-shirts to all of them in order to transmit to them their motivation and determination to succeed: “I wanted to told them what makes me run in races of more than 100 kilometers”, said the athlete Luis Alberto Hernando. Dr. Sánchez de Toledo expressed to the organizers of the race the appreciation of his research team for the 8,000 euros that they have raised since the first edition in 2008. </td></tr></table>comunica@vhir.org (VHIR)Tue, 23 Sep 2014 00:00:00 GMT"Among the clouds a clearing", third VHIR's Scientific Beer (22/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=194&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0194\2014_0194_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The third Scientific Beer is ready. We invite you to attend to the third Scientific Beer, next October 7, organized by the Patronage unit at Vall d’Hebron Institut de Recerca (VHIR), with the collaboration of Damm and TheDoctorFactory. After achieving an eight-thousand and finding a needle in a haystack, this time we look at the sky and find a clearing through the clouds. What does a storm mean in science? And in economics? Can we make predictions without creating alarm? Being able to distinguish between a downpour and a tsunami is a challenge that is part of both scientific and economic worlds. To solve all these questions, and the wants that may arise, we have three guests to offer their points of view: Patricia Pozo-Rosich. Neurologist at the Hospital Universitari Vall d’Hebron and head of the research group of Headache and Neurological pain at VHIR. Ricard Pujol. Head of the Immunology service at Hospital Universitari Vall d’Hebron and the Immunology research group at VHIR. Research advisor at the ICS. Vicente Ortún. Dean and professor at the Faculty of Economic Sciences at UPF. Researcher, exdirector and founder of the Centre d’Economia i Salut (CRES). Lluís Amiguet, journalist, La Contra on La Vanguardia, will moderate the third talk. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-</td></tr></table>comunica@vhir.org (VHIR)Mon, 22 Sep 2014 00:00:00 GMTThe European Medicines Agency grants the "orphan drug" designation to a viral vector tested in VHIR (19/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=193&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0193\2014_0193_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The European Medicines Agency (EMA) approves the first viral vector for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), a rare and lethal autosomal recessive hereditary disease caused by defects in nucleoside metabolism. The project is the result of a collaboration between the Neuromuscular and Mitochondrial Pathology Group, led by Dr. Ramon Martí, and the Gene and Cell Therapy Group, led by Dr. Jordi Barquinero.&nbsp; The disease is caused by mutations in the TYMP gene that encodes for thymidine phosphorylase, an enzyme involved in pyrimidine metabolism. A loss of this enzyme´s activity results in the accumulation of thymidine and deoxyuridine in the organism, which is particularly toxic to mitochondrial DNA synthesis. Disease symptoms generally appear in the second decade of life, with alterations in gastrointestinal motility and neurological defects, leading to progressive cachexia. To date, safe and efficient long-term treatments for the disease are lacking. Bone marrow transplantation from a healthy donor is the only treatment that has shown a positive effect, but the use of this procedure is extremely limited by the lack of donors and the high mortality rates observed in these patients.&nbsp; Using a mouse model of the disease, the VHIR researchers showed a potent effect when transferring bone marrow cells transduced with a viral vector containing a functional version of the TMYP gene. “However” Dr. Barquinero points out “given the high toxicity of bone marrow transplantation in MNGIE patients we decided to test a safer approach based on a liver-specific vector that had been successfully used in patients with hemophilia”. The researchers say that results obtained with the AAV-TYMP vector in the animal model, in collaboration with Dr. M. Zeviani from the Medical Research Council, Cambridge, are even more encouraging, as one single i.v. injection of the vector permanently corrects the metabolic defect in mice. The next step is to translate these results to the clinics. The designation of the vector as an orphan drug by the EMA will now allow the VHIR researchers to build an international consortium to apply for the European Program Horizon 2020 call on New Therapies for Rare Diseases. The consortium, whose main goal is to design and conduct a clinical trial, will be coordinated by Dr. Martí and includes other European groups, as well as the laboratory of Dr. M. Hirano, one of the leading experts in the disease, at the Columbia University in New York, and Genethon, a french non profit organis ation that will produce the vector in GMP conditions for its use in the clinics.&nbsp;&nbsp;&nbsp;&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Fri, 19 Sep 2014 00:00:00 GMTVHIR is holding a Multiple Myeloma patient education event (18/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=191&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0191\2014_0191_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Multiple myeloma is a cancer that starts at the bone marrow blood cells. In the last few years, important progress has been made in its treatment thanks to research, offering new hope to patients and their families. To report on this advances Vall d’Hebron Institute of Research (VHIR), together with online cancer patients community Patient Power and the collaboration of the Catalan Institute of Oncology (ICO), is holding an educational event for myeloma patients. The event will take place on Saturday October 11 at Vall d’Hebron Teaching Pavillion from 10 AM. Top researchers will speak at the event, such as Dr Mercè Gironella, Hematology doctor and head of Myeloma research at Hospital Universitary Vall d'Hebron and Dr Francesc Bosch, Head of Onco-Hematology and Experimental Hematology Research Group in the VHIR. The goal is that myeloma patients learn about what is being done in research and they can exchange views with other patients and researchers. An oncology nurse and a psycho-oncologist will also advice patients on how to deal with treatment side effects and how to manage emotions during the cancer journey. The researchers that will speak at the event are: - Dr Mercè Gironella. Hematology doctor and head of Myeloma research at Hospital Universitari Vall d'Hebron since 2010. - Dr Francesc Bosch. Head of Onco-Hematology and Experimental Hematology Research Group in VHIR. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style:</td></tr></table>comunica@vhir.org (VHIR)Thu, 18 Sep 2014 00:00:00 GMTThe series of conferences on Rare Diseases arrives at Madrid (17/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=189&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0189\2014_0189_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> With Dr. Llera this Wednesday, September 17, resume the first series of conferences on rare diseases organized by the Vall d’Hebron Institute of Research (VHIR). Also, with this seminar, the cicle arrives at Madrid, as by now all have taken place in Barcelona. Dr. Llera’s conference, Optimizing the investigation processes on rare diseases and orphan drugs, is the seventh seminar programmed about rare diseases, and is 8 out of the 12 seminars that the Fundación Areces sponsors that will take place in Barcelona and Madrid, coinciding with the 20th anniversary of the Institute. The next seminar will be in Barcelona, on September 23, with Dr. Jordi Llinares, Head of Department-Product Development Scientific Support European Medicines Ageny, London (United Kingdom). And the next event in Madrid will be on October 29 with Dr. Ségolène Aymé, chair of the Topical Advisory Group for Rare Diseases Orphanet and director of the Insitut Nationale de la Santé et de la Recherche Médical (France). Until now, the hospital has hosted half of the seminars, with Dr. Ignacio Burgos, driver and coordinator of the rare diseases workshop at the Senate; Dr. Alastair Kent, director at the Genetic Alliance UK; Dr. Christoph Klein, Physician-in-Chief and Chairman at the Dr. von Hauner Children’s Hospital in Munich (Germany); Dr. Paul Lasko<span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #555555; background-color: transparent; text-deco</td></tr></table>comunica@vhir.org (VHIR)Wed, 17 Sep 2014 00:00:00 GMTVall d'Hebron establishes international basis for the management of respiratory infections in critical patients (16/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=188&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0188\2014_0188_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Jordi Rello, head of the Intensive Care Service and the Clinical Research/Innovation in Pneumonia &amp; Sepsis (CRIPS) group at Vall d’Hebron Institute of Research (VHIR), and head of the Intensive Care Service at the Hospital Universitari Vall d’Hebron, has set the foundations for a new model to guide the management of intensive care patients that have developed respiratory infections associated to mechanical ventilation. The conclusions of the study have been published at The Lancet Respiratoy Medicine and have been presented recently at the ERS International Congress , held in Munich, Germany. The researcher from VHIR and the Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), together with a researcher from the Hospital de Clinicas in Porto Alegre, Brasil, and a researcher from Brisbaine, Australia, has revised nearly a thousand articles published the last decade about pneumonia and tracheobronchitis caused by mechanical ventilation received in the ICU. Thanks to this basis, according to Dr. Rello, “the study establishes a new paradigm with the progress made the last 10 years that will guide a new approach to the managing of these patients in the next 5 or 10 years”. The infection of the airways is the main cause of antibiotic administration at the ICU and it usually presents in the form of severe sepsis or septic shock in patients that receive mechanical ventilation. The study shows that nearly 30 per cent of these infections evolve to pneumonia and the 70 per cent in tracheobronchitis, but finds that their differentiation is difficult because it depends on a lot of variables. The article describes for the first time the differences between the 8 main pathogens and shows how many days it takes pneumonia to appear after intubation, based on data not published of the largest European collaboration network in the study of this disease, the EUVAP. </td></tr></table>comunica@vhir.org (VHIR)Tue, 16 Sep 2014 00:00:00 GMTDr. Elisa Carenza is awarded the "Dr. Ramón Ríos prize" (15/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=187&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0187\2014_0187_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Carenza received the award, worth 2.500 euro, in the category of first author under 30 of the best research work. The research work is directed by Dr. Anna Rosell, from the research group on Neurovascular diseases at theVall d’Hebron Institut de Recerca (VHIR), and Dr. Anna Roig, from the Institut de Ciència dels Materials del CSIC (ICMAB-CSIC), and was published this past January in the journal “Nanomedicine: Nanotechnology, Biology and Medicine”. The awarded and first author of the study, Dr. Elisa Carenza, did her doctorate with Drs. Rosell and Roig at VHIR and ICMAB-CSIC, under an agreement between the two institutions. The study focuses on the potential use of endothelial progenitor cells (EPCs) in strategies of neurological repair. For this purpose, they use a new technology based on the use of a external magnetic device to guide the EPCs, previously marked with iron oxide nanoparticles, to the brain. The authors show that the marked cells are viable and functional, and that they arrive successfully to the zones of interest on the brain when they are injected intravenously in model mice. The study concludes that is a secure and effective strategy to guide cells to specific zones of the brain, and it opens a new path on cell therapies driven to the regeneration of nerve tissue. The Foltra Foundation is a project that has the objective of helping physical and intellectual rehabilitation of the patients with neurological damage, central or peripheral, congenital or acquired, once the first phase of hospital assistance is over. The jury is formed by national and international Scientifics, experts on the fields of restorative neurogenesis and neuronal plasticity. The prize-giving ceremony will be announced soon and it is going to be during a scientific meeting taking place at the Foundation. </td></tr></table>comunica@vhir.org (VHIR)Mon, 15 Sep 2014 00:00:00 GMTThe campaign 'Migraine, get it out of the closet' aims to give visibility to those who suffer this disease (12/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=186&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0186\2014_0186_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Coinciding with the "Migraine awareness week", the Vall d’Hebron Institut de Recerca (VHIR) promotes the campaign “Migraine, get it out of the closet” with the aim of identifying who suffers this disease to help building awareness to society about its importance. “The patients suffering from migraine must know they are not alone, that there is a lot of people like them suffering from this disease, and together they can make their problem more known and thanks to this be able to improve their current quality of life and their future, thanks to investigation”, ensures Dr. Patricia Pozo, leader of the research group on Headache &amp; neurological pain at VHIR. In Spain, approximately 4 million people (12.5 per cent of the population) suffer from migraine. Most of them do it in silence. Migraine affects the quality of life of individuals and has huge social and economic impact (six days time off work and eight of underperformance each year per affected), and also on health care (one third of the neurological consults are because of this disease). Telling the story of the patients suffering from migraine and losing the fear of being recognized for it can be useful, not only for stopping being invisible, but also to raise awareness about the importance of this collective and their needs. </td></tr></table>comunica@vhir.org (VHIR)Fri, 12 Sep 2014 00:00:00 GMTThe research behind the ice bucket (09/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=185&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0185\2014_0185_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Ice Bucket Challenge has been, without a doubt, the viral of the summer and it has become a worldwide solidarity campaign thanks to the boost it has received by the social media. Anonymous people and, particularly, celebrities have made the initiative spread really fast. But, besides raising money all over the world, it has brought into the open the disease behind the ALS acronym, Amyotrophic lateral sclerosis. The Vall d’Hebron Institut de Recerca (VHIR) is a leading center in ALS research. The group of Peripheral nervous system, led by Dr. Josep Gámez, is currently working on three different research lines dedicated to the study of molecular mechanisms and genetic mutations of the disease. The group is also part of ALSUntangled, an international network of clinical experts with the aim of offering alternative or off-label ALS treatments. Besides the research team, the Vall d’Hebron University Hospital has an interdisciplinary unit devoted to the care of ALS patients, which serve nearly 100 out of the 400 affected that are in Catalunya. The cause of ALS is unknown and there is no cure or treatment available. It is a debilitating disease characterized by the loss of motor neurons which cause rapidly progressive weakness, muscle atrophy and the death of the patients by breathing failure. These days we have wanted to get to know better the research that is taking place at VHIR on ALS, and the stories behind some patients we treat at our hospital. Patients, assistants and researchers have positively appraised the ice bucket initiative that has been useful to raise awareness about the disease they suffer or dedicate great part of their time to. Now it’s time to keep fighting so that the disease and ALS patients are not forgotten, and because everyone that has become aware and want to collaborate does it also for this research. At VHIR you can make donations through the platform yoinvestigo.org, for research in general and also specifically for ALS research line. </td></tr></table>comunica@vhir.org (VHIR)Tue, 9 Sep 2014 00:00:00 GMTThe Gynecological Oncology group is awarded a grant for investigating endometrial cancer (05/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=182&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0182\2014_0182_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The program rewards projects that develop new technologies and promote the application of new ideas and technologies arising from collaborations between academia and industry. The other participants in the project are the Oncology-Pathology group from the IRB of Lleida, led by Dr. Xavier Matias-Guiu, and the companies ForMune and Althia. The Project, awarded a total of 650.769,80€ of which 107.350€ are for the VHIR group, focuses on the prediction of endometrial cancer recurrence and the design of new therapeutic strategies.&nbsp; The main goal is to find a method to determine the risk of disease recurrence, since identification of patients at high risk is critical for deciding the best therapeutic strategy and for a more rational design of clinical trials.&nbsp; 80% of patients with endometrial cancer have a good prognosis. Even so, it remains among the 10 most fatal cancers for women in developing countries due to its high incidence. Mortality is directly linked to the recurrence risk. Improving global survival and decreasing recurrence depends on the search of reliable biomarkers that permit identification of patients that may relapse. The project proposes to develop a predictive method based on the expression of the ANXA2 protein, and to use it as a tool for optimal categorization of patients susceptible to receiving treatment.&nbsp;&nbsp; Other research groups from VHIR have also received funds from this program. They include the Rheumatology team, led by Dr. Sara Marsal, in the Systemic Diseases group, and the Peripheral Nervous System group, led by Dr. Josep Gamez. The latter received funding for two projects within the same call, something unusual for such a highly competitive program. In all, VHIR has obtained 471.921€ for 4 different research projects in the 2014 call.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Fri, 5 Sep 2014 00:00:00 GMTLast places available for the Master's Degree in Translational Biomedical Research (02/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2013&num=276&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2013\2013_0276\2013_0276_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research will start on October 2014 the first edition of the new Master in Translational Biomedical Research, affiliated to Universitat Autònoma de Barcelona. The aim of the program is to generate excellent young researchers by providing them with the necessary combination of scientific and medical knowledge and skills to contribute successfully to the future of translational medical research. Since pre-registration opened last February, there have been two selection and admission processes for the first students on the first edition of the program. The last pre-registration period is open until September 30, 2014, and students can apply for one of the 10 grants that the VHIR offers. The Master’s Degree in Translational Biomedical Research is a unique program, for the environment, and because it addresses the world of biomedical research from the relationship between clinicians and researchers, for a more translational biomedical research. The main feature of this master programme is that takes place in a research institute recognized as Instituto de Investigación Sanitaria by the Instituto de Salud Carlos III, an organism depending of the Spanish Government. All the classes will be given at VHIR during the first semester by basic, clinical researchers and medical doctors who are in continuous contact with patients. The second semester will be devoted to the the master’s project and the practice internship that could be carried out in one of the 60 research groups from the 10 research areas of the Institute. <span st</td></tr></table>comunica@vhir.org (VHIR)Tue, 2 Sep 2014 00:00:00 GMTCAMFIC allocates the 0.7% of its budget on a project led by VHIR and PROSICS in Angola (13/08/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=176&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0176\2014_0176_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan Society for Family and Community Medicine (CAMIFIC) will donate nearly 12,000 euros, which is the 0.7% of its budget, to the project “Improvement of the treatment and quality of life of patients with tuberculosis in an area of Angola with high prevalence of the disease”, led by researchers from Vall d’Hebron Institute of Research (VHIR) and the International Health Program of the Catalan Institute of Health (PROSICS). The society concluded in a statement that the project was awarded for its research dimension, its commitment to telemedicine and its orientation towards the health co-development. The study is carried out at VHIR by the groups of Infectious Diseases and Microbiology. Since 2008, researchers and clinicians from Vall d’Hebron have worked closely with the Nossa Senhora da Paz Hospital, located in the centre-east of Angola. Since then, they are maintaining a telemedicine program to share clinical cases, and conducting several studies about the resistance to tuberculosis, the epidemiology of schistosomiasis, and the relationship between malaria and child mortality. A couple of months ago, they installed in Angola the first automatic system to diagnose multidrug-resistant tuberculosis, thanks to an agreement with the Probitas Foundation. </td></tr></table>comunica@vhir.org (VHIR)Wed, 13 Aug 2014 00:00:00 GMTDr. Patricia Pozo launches 'midolordecabeza.org' to deal with headache (08/08/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=175&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0175\2014_0175_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Patricia Pozo, head of the Headache &amp; Neurological Pain at Vall d’Hebron Institute of Research (VHIR), launched 'www.midolordecabeza.org', together with renowned neurologists from the Hospital Ruber Internacional in Madrid, the Hospital Clínico Universitario in Santiago de Compostela and Hospital Clínico in Valencia. The aim of the website is to organize the information about headache, including the latest advances in research, and make it accessible and useful for both patients and doctors. The website describes the different types of headache and its symptoms, how it is diagnosed, what the treatment consists of and which are the possible complications. It also includes a glossary with all the related terminology, and the explanation of the possible causes and consequences of the different types of headache. Research is also considered in the website. There is a detailed explanation about the main fields of study: detection of new headache entities, epidemiologic and genetic studies, basic research in experimental animals, cells or tissues, and functional neuroimaging research. The group led by Dr. Pozo at VHIR involves all these research lines, and pays special attention to migraine. Through the same website, it is possible to make a donation in order to support the research of this group of scientific excellence. Finally, the new website has two sections devoted to patients: the first one is focused on contents related to daily life or the occasional moments requiring attention such as work, holidays, pregnancy and exercise; the second one is a community which includes a forum for patients and doctors, and a medical history registry that can be used to connect patients with neurologists. </td></tr></table>comunica@vhir.org (VHIR)Fri, 8 Aug 2014 00:00:00 GMTDr. Rello is reelected chair of the Critically Ill Patients group of the ESCMID (07/08/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=174&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0174\2014_0174_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Jordi Rello, head of the Clinical Research and Innovation in Pneumonia &amp; Sepsis at Vall d’Hebron Institute of Research (VHIR), was reelected chair until 2016 of the Critically Ill Patients group of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). VHIR’s researcher founded the group 3 years ago and since then they have been very active, with several educational and research activities. They are currently conducting an international multicenter study with the aim to assess new definitions of respiratory diseases in the intensive care units for the Centers for Disease Control (CDC). Vall d’Hebron participates in the study, together with the Hospital General Universitario de Alicante and more than 30 hospitals from Australia, China, Lebanon, Turkey, Greece, Croatia, Italy, Slovenia, France and Portugal. They are also leading, at Vall d’Hebron and with the participation of European, American and Australian researchers, the first guidelines of clinical practice about the use of nebulized antibiotics in patients with artificial ventilation, with the collaboration of the Cochrane. The mission of the Critically Ill Patients group is to promote knowledge of infections of critically ill and ICU-admitted patients, with focus on infections from multidrug-resistant pathogens. The group consists of 35 active members, with the representation of intensivists, infectologists, microbiologists, and specialists in nursery, pharmacology, surgery and respiratory diseases. </td></tr></table>comunica@vhir.org (VHIR)Thu, 7 Aug 2014 00:00:00 GMTA study of the Infectious Diseases group at VHIR receives the Emanuel Wolinsky Award (06/08/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=173&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0173\2014_0173_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The editors of the prestigious journal Clinical Infectious Diseases have selected a study coordinated by the Infectious Diseases group at Vall d’Hebron Institute of Research (VHIR), to receive the Emanuel Wolinsky Award for the most outstanding clinical study published in the journal during 2013. The research, entitled “Ampicillin Plus Ceftriaxone is As Effective As Ampicillin Plus Gentamicin for Treating Enterococcus faecalis Infective Endocarditis (EFIE)”, was conducted through the Spanish network in infectious pathology (REIPI), and involved 17 Spanish hospitals and a Italian one. In this observational, nonrandomized and multicenter study, researchers demonstrated that a new antimicrobial pattern, made by Ampicillin plus ceftriaxone, appears as effective as ampicillin plus gentamicin for treating patients with enterococcus faecalis infective endocarditis. The main advantage of the new therapeutic harm is that can be used with virtually no risk of renal failure and regardless of the high-level aminoglycoside resistance status of E. faecalis. The editors of the journal highlighted that “this ambitious study provides useful clinical data in a field in which information is scarce and therapeutic alternatives are limited”. They also underlined that “it adds important data to the evolving paradigm of treating enterococcal IE and opens avenues for relevant clinical trials in the future”. VHIR researchers will receive the award on October 6th, at the ceremony of the Infectious Diseases Society of American (IDSA) in Philadephia, USA. To date, any article written by Spanish researchers had obtained this award, endowed with 1,000 euros. </td></tr></table>comunica@vhir.org (VHIR)Wed, 6 Aug 2014 00:00:00 GMTFirst meeting with the UK ME/CFS Biobank to standardize protocols (04/08/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=172&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0172\2014_0172_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Chronic Fatigue Working Group, led by Dr Jose Alegre at Vall d’Hebron Institute of Research (VHIR), held the first meeting with the UK ME/CFS Biobank in order to create and standardize a biobank on Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) at Vall d’Hebron University Hospital. Vall d’Hebron has the highest number of biological samples in Spain, from more than 1,600 CFS/ME patients collected over the last 20 years, according to the diagnostic criteria established by Fukuda et al. in 1994. The aim of the meeting was to establish the same diagnostic criteria and the same methodologies and laboratory parameters, so that VHIR researchers could collect and exchange samples with international biobanks in order to get consistent results. Dr. Alegre reported that “this initiative could revolutionize the understanding of this still poorly-understood disease and enhance development of new diagnostic biomarkers and treatments”. At this first meeting, leaders of both biobanks talked about the methodology and processing to collect human biological samples for use in research (blood, DNA, RNA, urine, cerebrospinal fluid, mononuclear cells (PBMC) and tissues such as brain and muscle). Afterwards, they shared the most appropriate methods to compare the immunological assays of fresh whole blood with frozen cells from the same patient. Finally, the meeting ended with a discussion about the ethical, social and legal issues that a biobank must accomplish. The UK ME/CFS Biobank, located at the London School of Hygiene &amp; Tropical Medicine (LSHTM), was founded in 2004 and it is the first repository of human biological samples from patients with ME/CFS in the world. </td></tr></table>comunica@vhir.org (VHIR)Mon, 4 Aug 2014 00:00:00 GMT"I was blocked when the doctors told me that they had a liver for me" (29/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=170&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0170\2014_0170_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> On September 21 the neighbourhood of Horta in Barcelona will host the Nick Festes d’Horta race dedicated to liver transplantation at Vall d’Hebron Institute of Research (VHIR). The organizer, María José Moscoso, shares her experience during the last 8 months after the liver transplantation and presents the latest news of the race. How did you receive the call from the hospital? Like if I was in a movie… I was blocked when the doctors told me that they had a liver for me. Although it was the long-awaited call, I was shocked. Fortunately, I didn’t have time to think about it. I took a shower, packed a few things and went to the Vall d’Hebron hospital. After some tests and screenings, I underwent surgery on October 5. Everything went very quickly. What do you remember about those days? It was a mental experience with very strange feelings.&nbsp; At the ICU I didn’t know if I had pain, but a few days later, I felt a severe back pain. Besides the pain, I felt lost, I didn’t know where my body was and the treatment to prevent rejection made me nervous, raised my pulse and caused me tremors. At the beginning I felt strange things. When did those feelings stop? When I decided to change the story, stopped fighting and started to accept my new liver instead. The most beautiful moment that I remember was when a few days after the surgery the doctor took me to the ultrasound scan room. I was crying because I knew that if something went wrong, the doctor would realize it in that test. Once in the room, the doctor touched my shoulder and explained to me, while we were watching the liver, how it worked. I felt that touch as an embrace and the good news as a miracle. I couldn’t believe that everything was ok! That was 8 months ago. How are you now? I’m fine after all that I’ve went through. I had hard moments, both emotionally and physically. The organ works perfectly and I only have a problem with the bile duct. Because of that, I have a catheter that it is a little bit uncomfortable, especially when I practice sport. Despite everything, I keep my normal life and people who know me, but didn’t know anything about my disease, don’t believe that I had a liver transplant. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #555555; background-color:</td></tr></table>comunica@vhir.org (VHIR)Tue, 29 Jul 2014 00:00:00 GMTVHIR coordinates the implementation of a diagnostic tool for Alpha-1 antitrypsin deficiency screening (24/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=168&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0168\2014_0168_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan Center of AATD, associated to the Pneumology Service and the research group at Vall d’Hebron Institute of Research (VHIR), is one of the coordinators of an international study for the implementation and validation of a diagnostic in vitro tool for Alpha-1 antitrypsin Deficiency (AATD) screening. The technique, called AlphaKit QuickScreen, provides information about the presence of the most frequent deficient mutation by capillary blood obtained from the fingertip in the outpatient clinic and within 15-30 minutes. The study is also coordinated by the Marburg Hospital in Germany and also participate the Biochemistry laboratories at Vall d’Hebron. The aim of is to allow the diagnosis of this rare disease to physicians who work in chronic obstructive pulmonary disease (COPD). With the new technique, Dr. Marc Miravitlles, coordinator of the Catalan Center of AATD, is convinced that "we will help with the prevention and treatment of lung emphysema, which is the most severe complication of the disease”. AATD is an inherited disease characterized by low levels of AAT and an increased risk of developing liver disease and emphysema at an early age. Despite it is one of the most common genetic diseases, it has an important underdiagnosis:&nbsp; to the Spanish registry estimates that only 4% of the cases in Spain have already been diagnosed. The laboratory diagnosis is performed by the quantitative determination of AAT in serum and the determination of the corresponding phenotype. Scientific societies and the World Health Organization recommend to perform a determination of AAT to every patient with COPD. However, Dr. Miravitlles alerts that “factors such as the lack of knowledge about the disease or methods and diagnosis paths can contribute to not perform”. The Catalan Center of AATD launched a new website with more information about the disease and their projects. </td></tr></table>comunica@vhir.org (VHIR)Thu, 24 Jul 2014 00:00:00 GMTDr. Gámez obtains funding for two projects in the "Retos-Colaboración 2014" call (22/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=167&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0167\2014_0167_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Peripheral Nervous System group, led by Dr. Josep Gámez at the VHIR, obtained funding for two collaborative projects with the biotech industry, awarded by the National Program for Reseach, Development and Innovation for 2014-2016. The granted amount was of 142,805 euros and 92,563 euros each. Dr. Gámez underlines the fact that ¨VHIR received support for two projects, despite the call being highly competitive”. He also highlights “the great importance of establishing collaborations with private industry for the advancement of biomedical research and the development of new treatments”. The first project involves the VHIR, Minoryx Therapeutics, Ascil Biopharm, Reig Jofre laboratories and the University Clinic of Navarra, and its goal is to develop a drug derived from pioglitazone for the treatment of x-linked adrenoleukodystrophy (ALD), a genetic neurodegenerative disease without cure for the moment. ALD is due to the accumulation of very long chain fatty acids in plasma and tissues (in particular the brain), and symptoms include behavioural, visual and auditive disorders, epileptic fits and dementia. Thus, it is a potentially lethal and debilitating disease on the long term, due to the damage in brain and nerves. Pioglitazone, already used for treating diabetes, has been explored in ALD and other neurodegenerative diseases, but with little clinical effect. According to the consortium, this is due to its low circulating levels in the central nervous system. They propose innovative strategies to design an analog or a new formulation of the molecule that allows increasing such levels and that represents a better overall risk/benefit than the currently commercialized form used for diabetes. This will also permit the generation of considerable intellectual property concerning the new formulations and their use. The goal of the second project, that involves VHIR, SOM Biotech, and the Universitat Autònoma de Barcelona (UAB), is to develop a drug for the treatment of amyloidosis by transthyretin (ATTR), an irreversible and fatal orphan disease caused by the aberrant accumulation of the transthyretin protein (ATTR) in different organs.&nbsp; ATTR belongs to the family of amyloid diseases, characterized by protein aggregation and accumulation of insoluble deposits in tissues and organs, with often fatal consequences. They have a total incidence of 3.3 for each million persons in Spain. The project´s aim is to take to the clinical phases a drug whose activity in ATTR treatment was detected by SOM Biotech via a virtual screening technique capable of identifying new therapeutic activities of existing drugs. Studies performed by the company show that, in different experimental settings, the drug can stabilize the </td></tr></table>comunica@vhir.org (VHIR)Tue, 22 Jul 2014 00:00:00 GMT'La soledad del abecedario' tells the story of a patient with chronic fatigue (21/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=166&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0166\2014_0166_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> “I was the athletics runner-up in Spain when I was 18 and now I can hardly find the words to describe the pain that people with chronic fatigue feel”. With this message, Fernando Novalbos presents ‘La soledad del abecedario’, a novel about the story of a patient with chronic fatigue. The 30% of the profits will be donated to the research in this syndrome, led at Vall d’Hebron Institute of Research (VHIR) by Dr. José Alegre. The main character is diagnosed by chance in a moment of his life in which “he has to deal with things related to love”, the author reported. It is a positive story in which the disease is not an impediment to achieve his challenges. Dr. Alegre recommends this book to all the society and especially to the patient’s families because it explains how this disease not only produces fatigue, but also induces a severe cognitive impairment. In this sense, he acknowledges the merit of the author because “the chronic fatigue syndrome presents serious reading and learning difficulties”. The book, edited by Ara Llibres, can be ordered from La Casa del Libro and other online sales platforms. </td></tr></table>comunica@vhir.org (VHIR)Mon, 21 Jul 2014 00:00:00 GMTThree undergraduate students share their experience at VHIR (18/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=165&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0165\2014_0165_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Carla Rossell, student of the first year of the Human Biology Degree at Universitat Pompeu Fabra and winner of the Catalan awards of excellence in high school: “I’ve seen at first hand the routine of a scientist and I love it! I chose the Vall d’Hebron because it is very renowned, very big, with many research areas and a lot of publications. I didn’t know which group to choose for the one-week traineeship, because I liked all of them, so I asked for advice to Núria Prim (lab coordinator). She introduced me to the Cell Signaling and Apoptosis group. I am very happy. I've done a lot of things! Honestly, I didn’t expect that I was going to do such an amount of techniques... Every member of the group told me about their projects and I participated in some of their tasks. It was very useful because I practiced different things that I learned on my first year in college, but I hadn’t practiced yet. All things considered, I would definitely repeat the experience! Daniel Villodres, student of the first year at the IES Banús high school in Cerdanyola del Vallès and participant of the 6th edition of the ‘Joves i Ciència’ programme of the Fundació Catalunya la Pedrera (watch the video): “I participated in the 6th edition of the ‘Joves i Ciència’ programme. They offered me a two-week traineeship at VHIR in order to learn the daily routine in a lab. To sum up, it’s been a great experience. I’ve learned new techniques, how do they work, and who is behind the outstanding research carried out at Vall d’Hebron… Great people! I also learned the aim of the research and the differences between clinicians and researchers. The work environment is great and I have realized that without clinicians, researchers wouldn’t have samples. And samples are essential to investigate proteins and find the cure of cancer, which is the main mission of the endometrial cancer research line conducted at the Research Unit in Biomedicine and Translational Oncology”. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: bold; color: #555555; background-color: transparent; text-decorati</td></tr></table>comunica@vhir.org (VHIR)Fri, 18 Jul 2014 00:00:00 GMTMeeting on nanomedicine, personalized medicine and biomarkers (14/07/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=160&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0160\2014_0160_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Nanomedicine is no longer a commitment to the future, but a reality more and more extended. Among its applications, researchers use it to obtain early diagnosis of different diseases, more efficient drugs and alternative therapies to the most aggressive treatments. Expoquimia, the reference event in the chemical industry, will have a space dedicated exclusively to nanomedicine, as in the last successful edition. The Vall d’Hebron Institute of Research (VHIR), which comprises and area dedicated to nanomedicine, is the organizer of this debate about the present and the future of nanomedicine, led by outstanding scientists and pharmacists. The meeting will take place on October 2 at Expoquimia and will deal with the current state of nanomedicine, personalized medicine and biomarkers. Participants will also focus in the perspectives of translation of the results to the society. Chaired by VHIR’s director, Dr. Joan Comella, three lecturers will participate in the meeting: Dr. Josep Tabernero, head of the Oncology Service at the Vall d’Hebron University Hospital, Dr. Víctor Franco, ICREA professor and researcher of the Catalan Institute of Nanoscience and Nanotechnology (ICN2), and Dr. Artur Palet, director of Business Development in Spain of Roche Diagnostics. <p style=" text-align: le</td></tr></table>comunica@vhir.org (VHIR)Mon, 14 Jul 2014 00:00:00 GMTVall d'Hebron improves burn scars by injecting adult stem cells from the patients (14/07/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=162&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0162\2014_0162_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Plastic Surgery and Burns Service at Vall d’Hebron University Hospital has successfully improved the treatment of burn scars, especially the ones that affect a considerable amount of skin surface, with the application of regenerative techniques using adult stem cells derived from the patient's adipose tissue. By now, the technique has been used in 2 patients, even though it can be applied in a wide number of patients, especially when they have consequences in large areas on the body. The patient’s tissue is obtained performing small precise incisions, from which the adipose tissue is extracted to isolate adult stem cells and the mesenchymal fraction. Once prepared, they are injected again into the scars and in the new tissue using tools of extremely small diameter that allow the introduction of a very small number of cells in each treated area. Thus, the mesenchymal stem cells create a microenvironment in the tissue that stimulates the growth of new vessels, secrete growth factors and promote new molecular structures that regulate the collagen deposition (part of the scar) and increase the elastic elements, which create, in long term, a new physical structure more alike to normal tissue. The aim of this innovative treatment is to improve the elasticity, flexibility and vitality of the scar tissue and diminish the unsightly consequences. The cells and implanted tissue can settle in the tissue and create a new structure inside the scars, which allows a better architecture of the new dermis, increasing its functional ability. This leads to a significant improvement in the quality of life of the patients, thanks to an increase in tissue flexibility, better hydration and improvement in the outlines of the scars. The benefits of this kind of therapy, which can be transferred to any other atrophy on soft tissue, are evident in a few months' time, as the stem cells regenerate and optimize the quality of the tissue after a reasonable time from the implant. Dr. Joan Pere Barret, head of the Plastic Surgery and Burns claims that “this is an innovative technique because we give biological treatment to the burns. Through the injection of cells and tissue we alter the biological structure of the tissue, performing a regenerative treatment that contrasts with the usual surgical techniques, which alter its form and function but not its quality, as we create new scars. With the new technique, we minimize the damage of the same surgery and provide benefits”. This technique goes in line with the new repair and plastic surgery, which aims at performing highly individualized and minimally invasive specialized treatments. In this regard, 5 years ago the Plastic Surgery and Burns service, through its team at Vall d’Hebron Institute of Research (VHIR), started conducting clinical research on the application of new techniques of regenerative surgery. An example of this is the use of stem cells in the reconstruction of serious facial disfigurement in children with Parry-Romberg syndrome, a pathology that produces severe malformations in the facial features. Thanks to a surgery performed at the Vall d’Hebron Hospital, the appearance and clinical evolution of these children is greatly improved. </td></tr></table>comunica@vhir.org (VHIR)Mon, 14 Jul 2014 00:00:00 GMTEls Amics de les Arts gave a benefit concert for research in child cancer at VHIR (12/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=157&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0157\2014_0157_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan pop band Els Amics de les Arts offered, on Friday 11, a benefit concert at the Bullring located in Olot, to present their last album ‘Només d’entrar hi ha sempre el dinosaure’. The A. Bosch foundation organized this performance with the aim to contribute to research in children’s cancer at the Vall d’Hebron Institute of Research (VHIR), led by Dr. Josep Sánchez de Toledo. All proceeds of the concert go to support the studies of the Translational Research in Child Cancer group. Specifically, the A. Bosch foundation is already collaborating in three projects to improve the therapies for child cancer, investigate the myelomeningocele (spina bifida) and the lupus erythematosus. The foundation was created in 2004 by Noel Alimentaria, with the aim to promote research and clinical solutions to childhood diseases.  The Olot city council, Natrus, La Fageda, Sant Aniol, Moritz and B-Crek sponsor the concert and the party that started two hours before with the performance of CyBee. </td></tr></table>comunica@vhir.org (VHIR)Sat, 12 Jul 2014 00:00:00 GMTA research team in VHIR reveals unexpected functions for a ribosomal protein in embryonic cells (10/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=156&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0156\2014_0156_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> A study published in PlosOne by the Molecular Pathology and Oncology group of the VHIR, directed by Dr. Matilde Lleonart,&nbsp; has revealed a crucial —and unexpected— role of a ribosomal protein, called P1, in the embryonic development of the nervous system. The project started 8 years ago, when the group led by Dr. Lleonart was seeking genes that could induce proliferation. They identified the P1 protein whose expression turned out to be increased in human tumors. In this study, performed in collaboration with researchers from the Leibniz Institute for Age Research, Jena, Germany, the authors wanted to understand the relevance of P1 in vivo. In other words, what happens when the protein is absent? They found that mice completely deficient for the protein (because both P1 alleles were inactivated) died before birth, while mice with one inactivated allele survived after birth but presented many defects such as reduced size, brain atrophty, an arrest in cell proliferation and an increase in cell death. The ribosome is a complex cellular factory where all new proteins are formed. Thus, defects in ribosomal proteins should lead to defects in protein synthesis. However, explains Dr. Lleonart, “the most surprising thing is that we did not find a defect in protein synthesis” Rather, P1 deficiency led to an increase in stress proteins that in turn results from an accumulation of mis-folded proteins. “This suggests that the protein has an extra-ribosomal function associated to protein folding” says Dr. Lleonart. Another unexpected result, according to the investigator, is that P1 disturbance particularly affects proliferating cells, very likely as a strategy to detect cellular stress and ensure their integrity as stem cells. “The role of the protein may depend on the tissue” concludes Dr. Lleonart, “since its deficiency </td></tr></table>comunica@vhir.org (VHIR)Thu, 10 Jul 2014 00:00:00 GMT"ISHR Best Poster Award" for a study by the Cardiovascular Diseases group (08/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=155&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0155\2014_0155_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Celia Fernandez-Sanz, a pre-doctoral student of Dr. Marisol Ruiz-Meana in the research group on Cardiovascular Diseases of Vall d’hebron Institute of Research (VHIR) has won the ISHR Best Poster Award in the recently concluded joint meeting of the International Society for Heart Research (ISHR) and the Council of Basic Cardiovascular Science of the European Society of Cardiology (Barcelona 3-6 of July 2014). The awarded work, conducted in collaboration with CNIC under the direction of Dr. Ruiz-Meana, describes a new mechanism of altered function in cardiac cells in advanced age, consisting in an alteration of the communication between two important organelles within those cells, the mitochondria and the sarcoplasmic reticulum, and used sophysticated analyses of cell physiology with in vivo confocal microscopy and advanced proteomic methods. In fact, the research groups in cardiovascular diseases have been the local hosts in this congress, the 32nd meeting of the European Section of the ISHR - a success well above the expected assistance: more than 250 participants on the 3rd of July and more than 700 total considering the joint meeting between ISHR and FCVB (Frontiers in Cardiovacular Biology), where the prized poster was also exposed. The goal of this international society is to promote the exchange of ideas between scientists and clinicians in the field of cardiovascular biology and medicine. Besides the award, it should be noted that Drs. Ruiz-Meana and Dr. García-Dorado, coordinator of the cardiovascular disease area, chaired some of the congress sessions, and Dr. Ruiz-Meana is member of the European Council of the ISHR. </td></tr></table>comunica@vhir.org (VHIR)Tue, 8 Jul 2014 00:00:00 GMTNew species detected in intestinal microbiota that make the difference between healthy and unhealthy individuals (06/07/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=154&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0154\2014_0154_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> A team of researchers from the Vall d’Hebron Institute of Research (VHIR), headed by Dr. Francisco Guarner, are the only Spanish participants in two studies that extend the MetaHIT Project. Both studies, published this Sunday July 6 in the Nature Biotechnology journal, represent one more step towards the knowledge of the intestinal microbiome. The first article provides an integrated catalog of gut microbial genes, which has increased from 3 to 10 million.&nbsp; Such a catalogue will allow scientists to determine the genetic and functional repertoire of a given gut microbiome and to understand how it is affected by geographical, temporal and physiological factors. Interestingly, the study reveals contry-specific gut-microbial signatures, as well as the presence of genes associated to antibiotic resistance. The second article explains how, thanks to a new approach in the analysis of complex metagenomic samples, more than 500 species have been identified in the human microbiome that were completely unknown until now. There is another landmark to add: not all the studied samples display such a high amount of unknown species. The intestinal flora of some individuals shows a smaller amount of unknown species and, in further analysis, it has been found to correspond to samples of patients diagnosed with Crohn’s disease. “This brings up new data which we have to explore in detail”, explains Dr. Francisco Guarner, “these species, unknown until now, will possibly make the difference between healthy and unhealthy people”. These data are highly relevant because they open the door to new strategies aimed at recovering all these species through nutritional interventions: administering probiotics or fibers and other prebiotics that help the selective growth of some species. These unknown bacteria are most certainly the “good bacteria”, as they are not the typical strains that produce an infection and this is the reason why they weren’t isolated never before. “In these cases the stool transplant is not useful because they are most likely labile species, strictly anaerobic and dependent of the environment and,most certainly wouldn’t survive outside the colon during the transplantation. The risk is that the transplant would favour the proliferation of non desirable species”, continues Guarner. </td></tr></table>comunica@vhir.org (VHIR)Sun, 6 Jul 2014 00:00:00 GMT